RTA 1701 / Biogen - LARVOL DELTA

RTA 1701: Expiry of patents related to composition-of-matter and method of use claims in US/ex-US between 2031 and 2037 (Reata) - Annual Report 2020

Patent • Psoriasis

RTA 1701: Expiry of patents related to composition-of-matter and method of use claims in US/ex-US between 2031- 2037 (Reata) - Annual Report 2019

Patent

Safety and PK/PD of RTA 1701 in Healthy Adults (clinicaltrials.gov) - P1; N=90; Completed; Sponsor: Reata Pharmaceuticals, Inc.; Recruiting ➔ Completed

Clinical • Trial completion

RTA 1701: Expiry of patents related to composition-of-matter and method of use in US/ex-US between 2031- 2037 (Reata) - Annual Report 2018

Patent